Clinical Trial Update: Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating induction with Zanubrutinib, Chidamide, and Rituximab with or without CHOP versus R-CHOP in newly diagnosed double-expressor diffuse la…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• Rituximab (rituximab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Li Zhiming | Conditions: BTK Inhibitors, Histone Deacetylase Inhibitor | Phase 2 | Status: NOT_YET_RECRUITING